Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and Protein Degradation and Inhibitors.
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Immunomodulation by anticancer cell cycle inhibitors
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Germline Lysine-Specific Demethylase 1 ( <i>LSD1/KDM1A</i> ) Mutations Confer Susceptibility to Multiple Myeloma
Postibrutinib outcomes in patients with mantle cell lymphoma
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
RETRACTED: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4